Evidence map›Paper›PMID 35756749›Full record

ArticleClinical kidney journal2022

Impact of the COVID pandemic on vascular access creation for haemodialysis in 16 Spanish haemodialysis centres.

María Dolores Arenas Jimenez, Angel Méndez, Karina Furaz, Ana Botella, Delfina Yetman, Ramiro Cazar, Mara Lisbet Cabana, Marc Handel, María Luz Sanchez, Margarita Delgado and 11 more

Open access · goldAbstract read
In one paragraph

Article in Clinical kidney journal, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
3.2field-weighted citation impact, top 9% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 1 country.

María Dolores Arenas JimenezDepartment of Nephrology Friat, Madrid, Spain.
Angel MéndezDepartment of Nephrology, Los Ilanos II Centre, Getafe, Madrid, Spain.
Karina FurazDepartment of Nephrology, Los Ilanos I Centre, Móstoles, Madrid, Spain.
Ana BotellaDepartment of Nephrology, Los Lauros Centre, Majadahonda, Madrid, Spain.
Delfina YetmanDepartment of Nephrology, Os Carballos I Centre; Vigo, Madrid, Spain.
Ramiro CazarDepartment of Nephrology, Santa Engracia Centre, Madrid, Spain.
Mara Lisbet CabanaDepartment of Nephrology, Os Carballos II Centre; Porriño, Madrid, Spain.
Marc HandelDepartment of Nephrology, El Castañar (Béjar) y las Encinas (Ciudad Rodrigo) Centres Salamanca, Spain.
María Luz SanchezDepartment of Nephrology, El Castañar (Béjar) y las Encinas (Ciudad Rodrigo) Centres Salamanca, Spain.
Margarita DelgadoDepartment of Nephrology, Los Pinos Centre, Medina Del Campo, Valladolid, Spain.
Maria Melissa VasquezDepartment of Nephrology, Los Olmos Centre, Segovia, Spain.
Isabel MartinezDepartment of Nephrology, Teixedal Centre; Lalin, Pontevedra, Spain.
Monica PereiraDepartment of Nephrology, Hospital Fundación Jimenez Diaz, Madrid, Spain.
Emilio González-ParraDepartment of Nephrology, Hospital Fundación Jimenez Diaz, Madrid, Spain.
Maria Soledad Pizarro-SánchezDepartment of Nephrology, Hospital Universitario Rey Juan Carlos, Madrid, Spain.
Ignacio Sanz GarayzabalDepartment of Nephrology, Hospital Universitario Infanta Elena, Valdemoro, Madrid, Spain.
Laura Rodriguez-OsorioDepartment of Nephrology, Hospital Universitario Villalba, Madrid, Spain.
José PortolesDepartment of Nephrology, Hospital Universitario Puerta de Hierro, Madrid, Spain.ORCID https://orcid.org/0000-0002-2114-1385
David HernánDepartment of Nephrology Friat, Madrid, Spain.
Blanca MirandaDepartment of Nephrology Friat, Madrid, Spain.
Renal Foundation’s Iñigo Álvarez de Toledo work team
Fundación Renal Española · ESHospital Universitario Fundación Jiménez Díaz · ESHospital Universitario Puerta de Hierro Majadahonda · ESHospital Universitario HM Madrid · ESHospital Universitario Rey Juan Carlos · ESCentro Nacional de Microbiologia · ESFundación Medina · ESHospital Universitario Infanta Leonor · ESFoundation for the Research Development and Application of Composite Materials · ESHospital Universitario de Getafe · ESHospital Universitario de Móstoles · ESUniversidade de Vigo · ESComplejo Hospitalario de Pontevedra · ESHospital General De Segovia · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: The coronavirus disease (COVID) pandemic has resulted in a major disruption in healthcare that has affected several medical and surgical specialties. European and American Vascular Societies have proposed deferring the creation of an elective vascular access (VA) [autologous or prosthetic arteriovenous fistula (AVF) or arteriovenous graft (AVG)] in incident patients on haemodialysis (HD) in the era of the COVID pandemic. The aim of this study is to examine the impact of the COVID pandemic on VA creation and the central venous catheter (CVC)-related hospitalizations and complications in HD patients dialyzed in 16 Spanish HD units of three different regions. Methods: We compared retrospectively two periods of time: the pre-COVID (1 January 2019-11 March 2020) and the COVID era (12 March 2020-30 June 2021) in all HD patients (prevalent and incident) dialyzed in our 16 HD centres. The variables analysed were type of VA (CVC, AVF and AVG) created, percentage of CVC in incident and prevalent HD patients, CVC-related hospitalizations and complications (infection, extrusion, disfunction, catheter removal) and percentage of CVC HD sessions that did not reach the goal of Kt (>45) as a marker of HD adequacy. Results: A total of 1791 VAs for HD were created and 905 patients started HD during the study period. Patients who underwent vascular access surgery during the COVID period compared with pre-COVID period were significantly younger, with a significant decrease in surgical activity to create AVFs and AVGs in older HD patients (>75 and >85 years of age). There was a significant increase in CVC placement (from 59.7% to 69.5%; P < 0.001) from the pre-COVID to the COVID period. During the COVID pandemic, a significantly higher number of patients started HD through a CVC (80.3% versus 69.1%; P < 0.001). The percentage of CVC in prevalent HD patients has not decreased in the 19 months since the start of the pandemic [414 CVC/1058 prevalent patients (39.4%)]. No significant changes were detected in CVC-related hospitalizations between the pre-COVID and COVID periods. In the COVID period, a significant increase in catheter replacement and the percentage of HD session that did not reach the HD dose objective (Kt > 45) was observed. Conclusions: COVID has presented a public health system crisis that has influenced VA for HD, with an increase in CVCs relative to AVFs. A decrease in HD sessions that did not reach the HD dose objective was observed in the COVID period compared with a pre-COVID period.

Indexed as

catheterchronic haemodialysisCOVIDSARS-CoV-2vascular access

Identifiers

PMID35756749
PMCPMC9217639
OpenAlexW4223899701

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.